Ainos, Inc.
AIMDNASDAQHealthcareBiotechnology
Previous close
$1.43
−$0.02 · -1.38%
Pre-market
$1.42
−$0.01 · -0.70%
Aug 24, 5:46 AM ET
AIMD company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
27
Expensive
Momentum
28
Weakening
Sentiment
62
Bullish
Risk resilience
15
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAinos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Chun-Hsien Tsai
- Listed since
- Jan 8, 2021
- Employees
- 41
Market position
Day range
Current $1.43
52-week range
Current $1.43
- Open
- $1.47
- Previous close
- $1.45
- Volume
- 16.36K
- 0.05× average
- Average volume
- 301.62K
- Average daily volume
- Market cap
- 10.53M USD
- Beta
- 2.48
- Market reference 1
- 50-day average
- $1.654
- -13.54% below average
- 200-day average
- $1.8261
- -21.69% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 17.59M USD
- P/E (TTM)
- -0.57×
- P/B (TTM)
- 3.2×
- P/S (TTM)
- 774.36×
- EV / EBITDA
- -1.9×
- Earnings yield
- -210.89%
- Free cash flow yield
- -66.38%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- -34987.54%
- Operating margin
- -101210.17%
- Net margin
- -106283.32%
- Return on equity
- -195.32%
- Return on assets
- -70.77%
- Return on invested capital
- -70.69%
Financial health
- Debt / equity
- 4.21×
- Current ratio
- 1.06×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 124.16K USD | 20.73K USD | 122.11K USD | 3.52M USD | 594.56K USD |
| Cost of goods sold | 4.8M USD | 52.6K USD | 375.85K USD | 2.11M USD | 184.18K USD |
| Gross profit | −4.68M USD | −31.87K USD | −253.73K USD | 1.41M USD | 410.38K USD |
| Research and development | 7.75M USD | 8.41M USD | 7.32M USD | 6.85M USD | 1.92M USD |
| Selling, general, and administrative | 1.56M USD | 5.4M USD | 5.64M USD | 8.54M USD | 2.36M USD |
| Operating expenses | 9.31M USD | 13.81M USD | 12.95M USD | 15.38M USD | 4.28M USD |
| Interest expense | 711.9K USD | 616.47K USD | 144.19K USD | 53.53K USD | 18.69K USD |
| Depreciation and amortization | 4.78M USD | 4.8M USD | 4.87M USD | 4.81M USD | 2.04M USD |
| Operating income | −13.99M USD | −13.84M USD | −13.21M USD | −13.98M USD | −3.87M USD |
| Net income | −14.77M USD | −14.86M USD | −13.77M USD | −14.01M USD | −3.89M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -0.62
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
AIMD peers
ETFs holding AIMD
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research AIMDresearch.disclaimer